|
|
|
Market Research Report
SPECIAL REPORT - Fueling the Drug Discovery Engine: Biotech Investment and Business Trends
|
SPECIAL REPORT - Fueling the Drug Discovery Engine: Biotech Investment and Business Trends published by Decision Resources, Inc. in June, 2008. This report consists of 50 Pages and the price starts from US $ 4500.
Abstract
Introduction
Promising new therapies and drug discovery approaches are within reach, but
the pharmaceutical and biotechnology industries face unprecedented scientifi
c, business, and regulatory challenges. Can the two industries develop and
exploit a mutually benefi cial synergy to ensure the long-term prosperity of
both? A range of strategic choices offers positive answers.
Get the Answers You Need to Shape Your Strategy
- Promising new therapies and drug discovery approaches are on the horizon,
but drug developers face unprecedented challenges in a changing drug discovery
landscape. What challenges confront both the pharmaceutical and
biotechnology industries? What challenges are particular to each industry?
What strategic choices are companies making today to advance drug discovery
and ensure their long-term prosperity?
- In 2007, corporate partnerships between biotech and pharmaceutical
companies for platform technologies surged. What factors account for
pharmaceutical companies' renewed interest in platform technologies? Which
technologies have attracted the greatest interest, and why? Which companies
were involved in 2007' s highest-value partnerships? How will these alliances
advance drug discovery and innovation?
- M&As among pharmaceutical, biotechnology, and related life science
companies have surged from 110 deals in 2002 to 315 deals in 2007. Which
pharmaceutical companies completed the highest-value biotech acquisitions in
2007? What will they gain? Do the same motives drive biotech companies' M&As?
What does it mean to call M&A "the new IPO"?
- Private and public fi nancing is the engine that drives biotechnology
companies-most cannot sustain themselves without it. How do investors infl
uence the direction of the biotech industry? What is the most important factor
in large investment decisions? What do the largest venture capital deals of
2007 reveal about trends in drug discovery fi nancing?
- Industry critics charge that pharmaceutical companies are lacking in
innovation, but the industry has launched many innovative drugs in recent
years. Which recently launched new molecular entities (NMES) operate on
novel targets or through new mechanisms of action? How have these drugs
performed in the marketplace? What are the benefi ts and risks of developing
fi rst-in-class novel NMEs?
Scope
- Corporate partnerships: within and across pharma and biotech
industries; high-value partnerships, 2007 and 2008; lead identifi cation,
development, optimization; target identifi cation, validation; therapeutic and
discovery platforms; biomarkers.
- Mergers & acquisitions: M&A surge in 2007; high-value
pharmaceutical M&As; pipeline-driven, high-value biotechnology M&As; M&A as
the "new IPO."
- Biotechnology fi nancing: venture capital; large VC investments;
Series A and seed fi nancings; IPOs.
- Drug discovery innovation: pharmaceutical industry under fi re;
NMEs approved, 2000-2007; novel approaches to cardiovascular disease,
diabetes, other diseases; sales of new drugs.
- Outlook: investor infl uence in biotechnology; M&As: aligning
interests; evolving business models.
Table of Contents
- Executive Summary
- Introduction
- Corporate Partnerships
- Lead Identifi cation
- Therapeutic Platforms
- Discovery Platforms
- Lead Development
- Partnering Strategy in Lead Identifi cation and Development
- Target Identifi cation and Target Validation
- Biomarkers
- Lead Optimization
- Mergers & Acquisitions
- Pharmaceutical Mergers & Acquisitions
- Biotechnology Mergers & Acquisitions
- M&A: The New IPO
- Biotechnology Financing
- Venture Capital
- Large VC Investments
- Series A and Seed Financings
- Initial Public Offerings
- Drug Discovery Innovation
- Outlook
- Investor Infl uence in Biotech
- M&A: Aligning Interests
- Evolving Industries
Tables
- 1. Select High-Value Lead Identifi cation Partnerships, 2007
- 2. Select High-Value Lead Development Partnerships
- 3. Select Biomarker Deals, 2007
- 4. Select Pharma-Pharma and Pharma-Biotech Mergers and Acquisitions, 2007
- 5. Select Biotech-Biotech Mergers and Acquisitions, 2007
- 6. Select Venture Capital Investments in Biotech, 2007
- 7. Select Series A Venture Capital and Seed Investments in Platform
Technologies, 2007
- 8. Select Biotech Initial Public Offerings, 2007
- 9. Select FDA-Approved New Molecular Entities with Novel
Mechanisms-of-Action, 2000-2007
Figures
- 1. Alliance Categories for Corporate Partnerships Potentially Worth At
Least $1 Billion, 2007
- 2. Development Phase of Top Lead Development Deals in 2007
- 3. All Life Science Mergers and Acquisitions, 2002-2007
- 4. Mergers and Acquisitions Among Pharmaceutical, Biotechnology, and
Related Life Science Companies by Deal Value, 2007
- 5. Investment Sizes of All Life Science-Related Venture Capital
Investments, 2007
- 6. Series A/Seed Financings in Biotechnology Platform Technologies, 2007
- 7. Combined 2007 Sales of FDA-Approved New Molecular Entities (NMEs) with
Novel Mechanisms-of Action, 2000-2007
|
 |
